Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers

30 juli 2026 uppdaterad av: Tuğçe Poyraz İşleyen, Bahçeşehir University

Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers: A Cross-Sectional Observational Study

Hemophilia is an inherited bleeding disorder characterized by recurrent musculoskeletal bleeding, particularly into joints, leading to impaired physical function and reduced functional performance. The 30-Second Sit-to-Stand Test (30STS) is a simple, reliable, and valid measure of lower extremity functional performance; however, evidence regarding its performance in individuals with hemophilia remains limited. This cross-sectional observational study aims to compare 30STS performance between adults with hemophilia and age-matched healthy controls and to investigate the relationship between 30STS performance, joint health, and activity level in individuals with hemophilia. Fifty-eight participants (29 individuals with hemophilia and 29 healthy controls) aged 18-35 years will be recruited. Participants will complete the 30STS. Individuals with hemophilia will additionally undergo joint health assessment using the Hemophilia Joint Health Score (HJHS) and activity evaluation using the Hemophilia Activities List (HAL).

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

Hemophilia is an inherited bleeding disorder caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), resulting in recurrent bleeding episodes. Repeated musculoskeletal bleeding, particularly hemarthrosis, may lead to progressive joint damage, reduced physical activity, muscle weakness, and impaired functional performance. Therefore, objective assessment of physical function is important for monitoring functional limitations and planning appropriate rehabilitation strategies in individuals with hemophilia.

The 30-Second Sit-to-Stand Test (30STS) is a simple, practical, and reliable performance-based assessment used to evaluate lower extremity strength, endurance, and functional mobility. Although the test is widely used in different populations, evidence regarding 30STS performance in individuals with hemophilia is limited. Comparing functional performance between individuals with hemophilia and healthy peers may provide valuable information regarding the functional impact of hemophilia and may contribute to clinical assessment approaches.

The aim of this cross-sectional observational study is to compare 30STS performance between individuals with hemophilia and age-matched healthy controls. Additionally, the study aims to investigate the relationship between 30STS performance, joint health status, and activity level in individuals with hemophilia.

A total of 58 participants aged 18-35 years will be included in the study, consisting of 29 individuals diagnosed with hemophilia A or hemophilia B and 29 age-matched healthy controls. All participants will perform the 30STS. Demographic characteristics, including age, height, and body weight, will be recorded. For participants with hemophilia, additional clinical information including hemophilia type, disease severity, bleeding history, and prophylaxis status will be collected.

Joint health status of individuals with hemophilia will be evaluated using the Hemophilia Joint Health Score (HJHS), and functional activity level will be assessed using the Hemophilia Activities List (HAL). The results of the 30STS will be compared between groups, and associations between functional performance, joint health, and activity level will be analyzed within the hemophilia group.

The findings of this study may contribute to a better understanding of lower extremity functional performance in individuals with hemophilia and may provide clinically relevant information for functional evaluation and rehabilitation planning

Studietyp

Observationell

Inskrivning (Beräknad)

58

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Ja

Testmetod

Icke-sannolikhetsprov

Studera befolkning

This study will include adult males aged 18-35 years with a diagnosis of hemophilia A or hemophilia B and age-matched healthy male controls. Participants with hemophilia will be recruited from the members of the Turkish Hemophilia Society. Healthy controls without hemophilia or other bleeding disorders will be recruited from the general population. A total of 58 participants, including 29 individuals with hemophilia and 29 healthy controls, are planned to be included in the study.

Beskrivning

Inclusion Criteria:

Hemophilia Group:

  • Diagnosis of hemophilia A or hemophilia B
  • Age between 18 and 35 years
  • Ability to walk independently
  • Willingness to participate in the study voluntarily

Healthy Control Group:

  • Age between 18 and 35 years
  • No history of hemophilia or other bleeding disorders
  • No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
  • No neurological, rheumatological, or severe orthopedic disorders
  • Willingness to participate in the study voluntarily

Exclusion Criteria:

Hemophilia Group:

- Acute joint bleeding episode within the previous 3 months

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Hemophilia Group
Participants aged 18-35 years with a diagnosis of hemophilia A or hemophilia B.
Healthy Control Group
Age-matched healthy participants without hemophilia or other bleeding disorders.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
30-Second Sit-to-Stand Test Performance
Tidsram: Baseline assessment (single assessment visit)
The primary outcome of this study is the performance on the 30-Second Sit-to-Stand Test (30STS). The test evaluates lower extremity functional performance by recording the number of correctly completed sit-to-stand repetitions within 30 seconds. The test will be performed once under standardized conditions in both the hemophilia group and healthy control group. Number of complete sit-to-stand repetitions performed from a standard chair within 30 seconds. Scores range from 0 to no fixed maximum, with higher scores indicating better lower extremity functional performance and muscle endurance.
Baseline assessment (single assessment visit)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Joint Health Status Assessed by Hemophilia Joint Health Score (HJHS)
Tidsram: Baseline assessment (single assessment visit)
Joint health status will be assessed in participants with hemophilia using the Hemophilia Joint Health Score (HJHS). The HJHS evaluates hemophilic arthropathy-related findings including swelling, muscle atrophy, crepitus, range of motion loss, and pain in target joints. Total HJHS score ranges from 0 to 124; lower scores indicate better joint health and higher scores indicate greater joint impairment.
Baseline assessment (single assessment visit)
Hemophilia Activities List (HAL)
Tidsram: Baseline assessment (single assessment visit)
Functional activity level in participants with hemophilia will be assessed using the Hemophilia Activities List (HAL), a patient-reported outcome measure evaluating limitations in daily activities and participation. The total score ranges from 0 to 100, with higher scores indicating better functional ability and fewer activity limitations.
Baseline assessment (single assessment visit)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Tığçe Poyraz İşleyen, Bahçeşehir University

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 augusti 2026

Primärt slutförande (Beräknad)

15 september 2026

Avslutad studie (Beräknad)

15 september 2026

Studieregistreringsdatum

Först inskickad

27 juli 2026

Först inskickad som uppfyllde QC-kriterierna

27 juli 2026

Första postat (Faktisk)

30 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

31 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be shared because there is no current plan to make individual-level data available to other researchers.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera